Synopsys, Inc. vs DENTSPLY SIRONA Inc — how do they compare? Synopsys, Inc. trades at $393.94 (market cap $75.13B), while DENTSPLY SIRONA Inc trades at $10.68 (market cap $2.19B). The key difference: Synopsys, Inc. is far larger — about 34.3× DENTSPLY SIRONA Inc's market cap, and DENTSPLY SIRONA Inc pays a 5.04% dividend while Synopsys, Inc. pays none. Which is the better fit depends on your goals.
| SNPS | XRAY | |
|---|---|---|
Market Cap | $75.13B | $2.19B |
Sector | Technology | Health |
52-Week High | $534.56 | $14.68 |
52-Week Low | $372.33 | $9.64 |
Enterprise Value | $82.36B | $4.26B |
Dividend Yield | — | 5.04% |
Signals from Pluang's Aura AI — not financial advice
Synopsys (SNPS) trades at $392.03, down 0.46% on the day, with a bearish technical signal from moving averages. The company has consistently beaten earnings estimates in recent quarters, including Q2 2026 EPS of $3.91 versus $3.67 expected. Revenue growth remains strong, with fiscal 2025 revenue reaching $7.05 billion, though net income margin compressed to 11.43% in 2026. Analyst consensus is overwhelmingly bullish with a $541.88 price target, representing significant upside potential.
The outlook for SNPS is positive based on fundamental strength and Wall Street optimism, but risks include high valuation multiples (P/E of 68.42), competitive pressures in semiconductor software, and integration challenges from the Ansys acquisition. The stock's near-term performance will hinge on Q3 2026 earnings results and continued execution in the expanding AI-driven chip design market.
XRAY trades at $10.99, down 3.43% on the day, reflecting ongoing challenges amid a bearish technical signal. The company reported a Q2 2026 earnings beat but faces declining revenue and negative profitability, with a net income margin of -14.99%. Cash flow trends show volatility, and the debt-to-asset ratio has worsened to 42.88% in 2025. Recent news highlights margin pressure and a class-action lawsuit inquiry, clouding the near-term outlook despite some institutional buying interest.
The investment outlook is cautious. While the stock trades below the consensus price target of $12.50, persistent net losses, high debt, and competitive pressures pose significant risks. Analyst sentiment is mixed with a 'Hold' consensus, suggesting limited upside until the company demonstrates sustained operational improvement and revenue stabilization.
Trailing returns across standard periods
Latest headlines on both assets
Synopsys is a provider of electronic design automation software, intellectual property, and software integrity products. EDA software automates the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. The firm's growing SI business allows customers to continuously manage and test the code base for security and quality. Synopsys' comprehensive portfolio is benefiting from a mutual convergence of semiconductor companies moving up-stack toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers alongside secular digitalization of various end markets benefits EDA vendors like Synopsys.
Read more on SNPS →Dentsply Sirona Inc is a global manufacturer and distributor of dental supplies and equipment. The company's operating segments include Technologies & Equipment, which is responsible for the design, manufacture, sales, and distribution of products including dental implants, CAD/CAM systems, orthodontic clear aligner products, imaging systems, treatment centers, instruments, as well as certain healthcare device products, primarily catheters
Read more on XRAY →